慢性髓性白血病中BCR-ABL1激酶结构域突变的反射性筛查 - Suppr | 超能文献

Reflexive Screening for BCR-ABL1 Kinase Domain Mutations in Chronic Myeloid Leukemia.

作者信息

Langabeer Stephen E, McCarron Sarah L, Haslam Karl, Preston Lisa

出版信息

Clin Lab. 2016;62(5):975-6. doi: 10.7754/clin.lab.2015.150938.

DOI:10.7754/clin.lab.2015.150938

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Reflexive Screening for BCR-ABL1 Kinase Domain Mutations in Chronic Myeloid Leukemia.慢性髓性白血病中BCR-ABL1激酶结构域突变的反射性筛查

Clin Lab. 2016;62(5):975-6. doi: 10.7754/clin.lab.2015.150938.

2

Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia.BCR-ABL1 激酶结构域介导的耐药性对慢性髓性白血病的影响。

Leuk Res. 2014 Jan;38(1):10-20. doi: 10.1016/j.leukres.2013.09.011. Epub 2013 Sep 23.

3

BCR-ABL1 mutation screening in chronic myeloid leukaemia: is next now?慢性髓性白血病中的BCR-ABL1突变筛查：下一个会是现在吗？

Lancet Haematol. 2019 May;6(5):e236-e237. doi: 10.1016/S2352-3026(19)30046-8.

4

Molecular monitoring and mutations in chronic myeloid leukemia: how to get the most out of your tyrosine kinase inhibitor.慢性髓性白血病的分子监测与突变：如何充分利用酪氨酸激酶抑制剂

Am Soc Clin Oncol Educ Book. 2014:167-75. doi: 10.14694/EdBook_AM.2014.34.167.

5

F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib.F317L BCR-ABL1激酶结构域突变与一名接受达沙替尼治疗的慢性粒细胞白血病患者持续的主要分子反应相关。

Leuk Res. 2011 Jul;35(7):e118-20. doi: 10.1016/j.leukres.2011.03.021. Epub 2011 Apr 12.

6

Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia.慢性髓性白血病中BCR-ABL1激酶结构域及其他部位的突变

Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl:S120-8. doi: 10.1016/j.clml.2015.02.035.

7

The effectiveness of interferon-α combined with imatinib in patient with chronic myeloid leukemia harboring T315I BCR-ABL1 mutation.α干扰素联合伊马替尼治疗携带T315I BCR-ABL1突变的慢性髓性白血病患者的疗效

Leuk Lymphoma. 2018 Dec;59(12):3018-3019. doi: 10.1080/10428194.2018.1443329. Epub 2018 Apr 4.

8

Prolonged treatment-free remission in chronic myeloid leukemia patients with previous kinase domain mutations.既往存在激酶结构域突变的慢性髓性白血病患者的长期无治疗缓解

Haematologica. 2020 May;105(5):e225-e227. doi: 10.3324/haematol.2019.234179. Epub 2019 Sep 19.

9

Presence of a new BCR-ABL kinase domain mutation, C330G in an imatinib naive patient with chronic myeloid leukemia: very low prevalence of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from eastern India.一名初治慢性髓性白血病患者中存在新的BCR-ABL激酶结构域突变C330G：印度东部慢性髓性白血病患者中BCR-ABL激酶结构域突变的极低发生率

Leuk Lymphoma. 2009 Apr;50(4):663-6. doi: 10.1080/10428190802714032.

10

In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.在接受二线酪氨酸激酶抑制剂治疗的慢性髓性白血病患者中，在出现警示时对BCR-ABL1进行深度测序可能有助于灵敏检测新出现的耐药突变体。

BMC Cancer. 2016 Aug 2;16:572. doi: 10.1186/s12885-016-2635-0.